Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 76

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 76
---
 which UCSF’s employee, Dr. Robert Flavell, will conduct research on a project entitled “Investigation of 18F-fluorodeboronation method for PSMA targeting ligand radiolabeling and evaluation in prostate cancer models” (the “Research Program”). Under the terms of the Sponsored Research Agreement, the Company will bear the total cost of $291,607 of the Research Program.

| ● | Develop                                                                                                                                        
 PSMA-B as a potential diagnostic and therapeutic molecule in pre-clinical models in collaboration with academic nuclear medicine               
 programs. Shuttle Pharma has licensed the intellectual property for the prostate cancer predictive biomarker test from inventors               
 and will seek additional investment from NIH by applying for grant applications and from the public market to advance clinical pre-development 
 through its Shuttle Diagnostics entity.                                                                                                        |

Our Strategy

Our goal is to maintain and build upon our leadership position in radiation sensitization. We plan to develop Ropidoxuridine and the HDAC6 inhibitor (SP-2-225) and, if approved by the FDA, commercialize our product candidates for the treatment of cancers. While this process may require years to complete, we believe achieving this goal could result in new radiation sensitizer and immunotherapy products. Key elements of our strategy include:

| ● | Capitalize                                                                                                                                  
 on Ropidoxuridine as an orally available, small molecule radiation sensitizer. To date, there is one drug (Cetuximab, a monoclonal          
 antibody) approved by the FDA specifically as a radiation sensitizer. If we are successful in developing Ropidoxuridine and obtaining       
 FDA approval, a small molecule sensitizer would then be enabled for clinical applications for radiation sensitization indications.          |
| ● | Expand                                                                                                                                      
 our leadership position within radiation sensitizers. In addition to our traditional radiation sensitizers, we plan to advance              
 our near-term pipeline to include radiation sensitizers for proton therapy. Proton Therapy is growing worldwide as a form of radiation      
 therapy due to its unique beam shaping characteristics. As a result, this new technology offers a major opportunity for Shuttle Pharma      
 to strive to develop an innovative and well-tolerated drug for proton therapy sensitization.                                                |
| ● | Execute                                                                                                                                     
 a disciplined business development strategy to strengthen our portfolio of product candidates. We have built our current product            
 pipeline through in-house discovery, development, partnerships with leading academic institutions and through in-licensing. We will         
 continue to evaluate new in-licensing opportunities and collaboration